How GLP-1s impact the heart and kidneys of veterans with type 2 diabetes​How GLP-1s impact the heart and kidneys of veterans with type 2 diabetes 

Public interest in drugs known as glucagon-like peptide-1 receptor agonists, also called GLP-1 RAs, has surged in recent years, with popular types like semaglutide (sold under brand names like Ozempic and Wegovy) becoming known for their weight-loss effects. ​Public interest in drugs known as glucagon-like peptide-1 receptor agonists, also called GLP-1 RAs, has surged in Read More

STAT+: Novo nears release of high-stakes data on Alzheimer’s and GLP-1s​STAT+: Novo nears release of high-stakes data on Alzheimer’s and GLP-1s 

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Today, we report on how lawsuits linked to Covid-19 are gaining prominence under the Trump administration. We also await Novo results on GLP-1 effects on Alzheimer’s, and more. The need-to-know this morning Alkermes increased Read More

STAT+: Can GLP-1 drugs treat Alzheimer’s? Novo Nordisk will soon announce key results​STAT+: Can GLP-1 drugs treat Alzheimer’s? Novo Nordisk will soon announce key results 

Within the next two weeks, Novo Nordisk is expected to announce the results of perhaps the most ambitious studies yet of its blockbuster GLP-1 drug semaglutide — whether the medicine can help slow the progression of Alzheimer’s disease.  The Danish company has repeatedly stressed that these are risky studies, since there hasn’t yet been definitive Read More

STAT+: Novo Nordisk’s $199 Ozempic deal shows what telehealth platforms can do for pharma​STAT+: Novo Nordisk’s $199 Ozempic deal shows what telehealth platforms can do for pharma 

On Monday, Novo Nordisk announced a discount on its popular drugs for diabetes and obesity, Ozempic and Wegovy, cutting prices for the lowest doses to $199 when patients pay cash through Novo’s pharmacy NovoCare.  Patients searching for those deals online, though, won’t always get funneled to the drugmaker’s sites. Instead, the first results they may Read More